CryoCloud Funding News- Dutch Biotech CryoCloud Raises €2Mn Funding

The funding round was led by Nina Capital, a healthtech investor from Barcelona, with support from Value Creation Capital, ROM Utrecht, and the Utrecht Health Seed Fund.

CryoCloud wants to make cryo-EM—a Nobel Prize-winning method for viewing 3D protein structures—easier to use by automating it in the cloud. Its platform lets researchers see and study proteins in high detail, saving both time and money compared to traditional methods.

“With CryoCloud, we have built the first cryo-EM platform that allows scientists to access petabytes of storage and dozens of GPUs in minutes rather than months, enabling scientists to run their cryo-EM projects faster and more effortlessly,” said CryoCloud CEO and
co-founder Robert Englmeier, PhD.

“It’s a turnkey solution: our customers tell us their productivity rates have increased and they have been able to expand and run their cryo-EM projects with greater efficiency and reliability. Our platform already delivers huge benefits today - and we’re excited to use this funding round to build the next generation of algorithms that will make the analysis even easier.”

With this new funding, CryoCloud has now raised a total of €2.8 million, including a €500,000 pre-seed round in 2023. The company already has customers in over 25 countries, including universities, biotech firms, and pharmaceutical companies.

Cryo-EM is becoming more popular in biology and drug research because it can show proteins in very fine detail, which helps in designing new drugs. However, it has usually only been used in top labs because it needs expensive equipment and expert knowledge.

CryoCloud’s platform helps remove the usual challenges of using cryo-EM by offering the analysis through cloud computing. The company uses its own machine learning tools to help scientists handle large amounts of structural data. Drugs developed with methods like cryo-EM are more likely to succeed in early testing, making this technology important for drug research.

“We are proud to continue to support this highly specialised team transforming structural biology, starting with an innovative approach to cloud resources and workflow solutions for cryo-EM data analysis,” said Marta G. Zanchi, founder and Managing Partner at Nina Capital. “We are excited to be joined in this latest round by new investors with domain expertise, all of whom recognise the timeliness of this market need and the relevance of CryoCloud's product.”

About CryoCloud

CryoCloud is a cloud-based biotech company that provides an online platform for analyzing cryo-EM data. This helps scientists figure out protein structures faster and supports drug discovery. The goal is to make cryo-EM easier, cheaper, and more automated. By using the web-based platform, users don’t need to worry about setting up or maintaining special hardware or software it’s all handled in the cloud.